Welfide Report issue

For profit Phase 1 Phase 2 Phase 3 Phase 4
Founded: Higashi-Yoshitomi-mura Japan (1952)
Status: Acquired by Mitsubishi Tanabe (2001)

Organization Overview

First Clinical Trial
None
First Marketed Drug
1988
cephalexin (keflex)
First NDA Approval
None
Last Known Activity
1988

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

YOSHITOMI | Yoshitomi Pharmaceutical

Active Ingredients

Marketed Drugs (1)

cephalexin (keflex) (1988)

Drugs in Phase 4 Trials (8)

Key: Welfide (0) Acquired (8)

acetylsalicylic acid (aspirin) (1 trial)

immune globulin (human) (Gamastan) (9 trials)

inactivated influenza vaccine (17 trials)

lactic acid (1 trial)

potassium chloride (klor-con) (1 trial)

rituximab (rituxan) (2 trials)

shinbaro (3 trials)

sodium chloride (4 trials)

Drugs in Phase 3 Trials (16)

Key: Welfide (0) Acquired (16)

antihemophilic factor viii human (Hemofil M) (1 trial)

antihemophilic factor viii (Recombinant) (Adynovate) (3 trials)

bacille calmette-guerin (2 trials)

celecoxib (celebrex) (2 trials)

Filgrastim (neupogen) (2 trials)

fluarix (1 trial)

gc1102 (5 trials)

gc1111 (2 trials)

gemcitabine (gemzar) (1 trial)

hantavax (2 trials)

hepatitis b immune globulin (human) (BayHep B) (2 trials)

human placenta hydrolysate (2 trials)

idursulfase (elaprase) (4 trials)

immuncell-lc (6 trials)

inactivated varicella vaccine (1 trial)

Tetanus and diphtheria toxoids adsorbed (Decavac) (2 trials)

Drugs in Phase 2 Trials (27)

Key: Welfide (0) Acquired (27)

acellular pertussis vaccine (including diptheria and tetanus toxoids) (Tripedia) (1 trial)

albumin (Human) (Plasbumin) (1 trial)

aldesleukin (Proleukin) (1 trial)

allogeneic natural killer cells (2 trials)

aluminum hydroxide (Gaviscon) (1 trial)

autologous t cells (1 trial)

crv-101 (1 trial)

cyclophosphamide (cytoxan) (1 trial)

diphtheria, tetanus and whole cell pertussis vaccine (Boostrix) (2 trials)

fludarabine (fludara) (1 trial)

fluorouracil (efudex) (1 trial)

folfirinox (1 trial)

gc3111 (1 trial)

gc5131 (1 trial)

human immunoglobulin g (1 trial)

irinotecan (Camptosar) (1 trial)

leucovorin (1 trial)

levoleucovorin (fusilev) (1 trial)

live attenuated varicella vaccine (Varivax) (2 trials)

lonicera japonica (1 trial)

mg1111 (3 trials)

mg4101 (1 trial)

Pegfilgrastim (1 trial)

rpa102 (1 trial)

suduvax (1 trial)

tramadol (Ultram) (1 trial)

varicella zoster virus glycoprotein e antigen (Shingrix) (1 trial)

Drugs in Phase 1 Trials (15)

Key: Welfide (0) Acquired (15)

agalsidase beta (Fabrazyme) (1 trial)

allogeneic hematopoietic stem cells (Hemacord) (2 trials)

apolipoprotein kringle v (1 trial)

crv 101 (1 trial)

darbepoetin alfa (aranesp) (1 trial)

epoetin (Epogen) (1 trial)

gc1109 (1 trial)

gc-1118 (1 trial)

gcc-4401 (2 trials)

linagliptin (tradjenta) (2 trials)

margetuximab (Margenza) (1 trial)

metformin (glucophage) (2 trials)

mg1113 (2 trials)

pexastimogene devacirepvec (1 trial)

rivaroxaban (xarelto) (1 trial)

Drugs in Other Trials (10)

Key: Welfide (0) Acquired (10)

bismuth (1 trial)

clarithromycin (biaxin) (1 trial)

lactobacillus plantarum (1 trial)

lactococcus lactis (1 trial)

maltodextrin (2 trials)

metronidazole (flagyl) (1 trial)

pantoprazole (protonix) (1 trial)

procaine benzylpenicillin (novocaine) (1 trial)

tetracycline (tetrex) (1 trial)

tivantinib (1 trial)

Indications

Overview

  • Highest Phase: None
  • # of Trials: 101
  • # of Trial APIs: 76